INVESTOR RELATIONS

PRESS RELEASES

18-Dec-2008 Amarin Opens U.S. R&D Office In Mystic, Connecticut
6-Nov-2008 Amarin To Present at 10th Annual Rodman & Renshaw Healthcare Conference
5-Nov-2008 Amarin CEO Featured On CEOcast.com
3-Nov-2008 Amarin Appoints Dr. Lars Ekman As Non-Executive Director
25-Sep-2008 Amarin Announces Financial Results for Second Quarter 2008
23-Sep-2008 Amarin Appoints Dr. Mehar S. Manku To Chief Scientist
17-Sep-2008 Amarin Announces Second Quarter 2008 Results Conference Call
17-Sep-2008 Amarin Appoints Dr. Paresh Soni as SVP and Head of Development
31-Jul-2008 Amarin Announces Annual General Meeting Concluded
22-Jul-2008 Amarin Proceeding to Phase 3 with AMR101 for Hypertriglyceridemia
8-Jul-2008 Amarin Notice of Annual General Meeting
22-May-2008 Amarin announces completion of the first tranche of $60 million private placement. Appoints Four New Directors to Board.
19-May-2008 Amarin announces financial results for first quarter 2008
19-May-2008 Amarin announces financial results for fourth quarter and full year 2007
14-May-2008 Amarin announces private placement for up to $60 million
3-Mar-2008 Amarin Secures Global Intellectual Property Rights for Lipid Programs
11-Feb-2008 Amarin regains compliance with Nasdaq Listing Requirements
4-Feb-2008 Amarin appoints Dr. William Mason as Lead Independent Director
18-Jan-2008 Amarin provides business update and announces implementation of Reverse Stock Split
10-Jan-2008 Amarin to commence Phase II Trial with AMR101 in Age Associated Memory Impairment
Page 1 of 2